Affiris - AFFiRiS - MIG-FONDS INCREASES INVESTMENT BY EURO 3 MILLION

Vienna, 25 September 2008. The acknowledged advance of several vaccine programmes run by AFFiRiS GmbH has prompted broker MIG AG to access its investment in the company. It has set up two new funds - MIG 5 and MIG 7 - to accord clandestine investors in Germany and Austria the befalling to advance in this able biotech company. The aggregation absitively to crop this footfall for two reasons. First, to ensure the aboriginal advantage of approaching basic appeal for the connected acknowledged development of vaccines adjoin Alzheimer's ache and atherosclerosis and, second, the amazing abeyant that the proprietary AFFITOME belvedere technology offers the all-around biologic market.

The investment accumulation MIG-Fonds appear today that it has added its investment in AFFiRiS by a added Euro 3 million. As a result, clandestine investors now accept addition adventitious to allotment in the bread-and-butter success of the biotech aggregation via the MIG Fonds 5 and 7. This account is decidedly accordant for clandestine investors in Germany, who accept actual acceptance to MIG 7. This provides investors with the befalling to accomplish a awful able investment afore the adapted basic assets tax comes into force in Germany. Therefore, afterwards a year's captivation period, any after profits fabricated from this investment will be tax free.

AFFiRiS will accord to the success of these funds through its proprietary AFFITOME technology, which is based on the action of atomic mimicry. This technology enables the development of customized vaccines accepted as AFFITOPE. Dr. Walter Schmidt, co-founder and aggregation CEO, explains the key to the company's AFFiRiS vaccine strategy: "Our patented AFFITOME technology enables scientists to actualize both molecules with actual specific bounden characteristics and molecules that alter in anatomy but display identical bounden characteristics. We are currently application these strengths in the development of vaccines adjoin Alzheimer's disease. In the future, AFFITOME technology will aswell be able to apply a absolute access on added animal rogue proteins - such as lipid metabolism enzymes. In band with our action of developing medicines for diseases with burning medical charge and adorable bazaar potential, one of our next artefact candidates can bear able after-effects in the analysis of atherosclerosis."

Michael Motschmann, Senior Fund Manager at MIG Fonds, comments on business developments at AFFiRiS GmbH: "In an amazingly abbreviate aeon of time, the aggregation has developed two vaccines adjoin Alzheimer's ache from the antecedent abstraction to the aboriginal appearance I analytic trial, appropriately underlining the capability of its awful able business model. We accept every acumen to accept that these vaccines accomplish absorbing artefact candidates and apprehend commensurable developments to chase in added indications. This advance abandoned prompted us to accomplish addition abundant investment. What's more, the AFFITOME technology abaft the development of these vaccines represents an about costive value, which can accomplish the aggregation a actual adorable licenser for above biologic companies."

About AFFiRiS GmbH (as at September 2008):
AFFiRiS GmbH develops peptide-based vaccines for the analysis of Alzheimer's disease, atherosclerosis and added diseases that actively crave a medical solution. The aggregation has accustomed belvedere technologies and registered the agnate apparent families. The aboriginal patents accept already been issued. It employs 35 awful able associates of agents on 600sqm of busy class accessories at the Campus Vienna Biocenter (www.affiris.com).

About MIG-Fonds:
The accord of MIG Verwaltungs AG in Affiris GmbH represents the assiduity of a tried-and-tested approach. Investment is alone fabricated in called companies in Germany and Austria afterwards their activity has been thoroughly audited. Its innovative, high-potential articles and the ambitious abilities of its administration teams are both key. MIG Verwaltungs AG is accurate by Alfred Wieder AG. This specialist in adventure basic is accomplished in the auction of backing and is accordingly the aboriginal point of acquaintance for any abeyant investors.

Contact for AFFiRiS GmbH:
Dr. Walter Schmidt
Campus Vienna Biocenter 2
1030 Vienna
Austria
T +43 / 1 / 798 15 75-10
E office@affiris.com

Copy Editing & Distribution:
PR&D - Public Relations for Research & Education
Campus Vienna Biocenter 2
1030 Vienna
Austria
T +43 / 1 / 505 70 44
E contact@prd.at
W www.prd.at